NCT05440305已完成不适用
Castleman Disease - Diagnosis and Surgery
Charles University, Czech Republic0 个研究点目标入组 20 人开始时间: 2011年1月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 主要终点
- 5 year survival
研究概览
简要总结
Observation study on patients with unicentric form of Castleman disease, evaluation of surgical treatment benefit. Observation of surgical treatment strategy.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patient with unicentric form of Castleman disease
- •underwent surgery resection
排除标准
- •multilocalised Castleman disease
结局指标
主要结局
5 year survival
时间窗: each 6 months checkup, up to 150 weeks, from date of randomization until the date of first documented progression
surgery treatment success
recurence rate
时间窗: each 6 months checkup, up to 150 weeks, from date of randomization until the date of first documented progression
surgery treatment success
次要结局
未报告次要终点
研究者
Jiri Molacek
Principal investigator
Charles University, Czech Republic
相似试验
终止
不适用
The Treatment of Cartilaginous Lesions and Concomitant Anterior Cruciate Ligament ReconstructionCruciate Ligament RuptureCartilage InjuryNCT04184687Istituto Ortopedico Rizzoli4
已完成
不适用
Collagenase is a Common Treatment of MCP and PIP Joint Contractures in Dupuytrens DiseaseDupuytren ContractureNCT03331926Jeppe Lange199
招募中
不适用
A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe AnthraxAnthraxNCT06365073Qin Ning80
已完成
不适用
Mild Carpal Tunnel SyndromeCarpal Tunnel SyndromeNCT00981565North Karelia Central Hospital88
已完成
不适用
Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 YearsHER-2 Positive Breast CancerNCT01433926Asociación para el Progreso de la Oncología en Málaga114